<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00677716</url>
  </required_header>
  <id_info>
    <org_study_id>PPHM 0503</org_study_id>
    <nct_id>NCT00677716</nct_id>
  </id_info>
  <brief_title>Dose Confirmation Study of Cotara for the Treatment of Glioblastoma Multiforme at First Relapse</brief_title>
  <official_title>Open-label, Dose Confirmation Study of Interstitial 131I-chTNT-1/B MAb (Cotara®) for the Treatment of Glioblastoma Multiforme (GBM) at First Relapse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peregrine Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peregrine Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cotara® is an experimental new treatment that links a radioactive isotope (iodine 131) to a
      targeted monoclonal antibody. This monoclonal antibody is designed to bind tumor cells and
      deliver radiation directly to the center of the tumor mass while minimizing effects on normal
      tissues. Cotara® thus literally destroys the tumor &quot;from the inside out&quot;. This may be an
      effective treatment for glioblastoma multiforme, a malignant type of brain cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To confirm the safety and tolerability of the Maximum Tolerated Dose (MTD) of 131I-chTNT-1/B
      MAb given as a single interstitial infusion in patients with glioblastoma multiforme at first
      relapse.

      To estimate overall survival, progression free survival and proportion of patients alive at
      six months after treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To confirm the safety and tolerability of the maximum tolerated dose</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To estimate overall survival, progression free survival and proportion of patients alive at six months after treatment.</measure>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <arm_group>
    <arm_group_label>131I-chTNT-1/B MAb (Cotara)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>131I-chTNT-1/B MAb (Cotara)</intervention_name>
    <description>Given as a single interstitial infusion over approximately 25 hours at a dose of 2.5 mCi/cc.</description>
    <arm_group_label>131I-chTNT-1/B MAb (Cotara)</arm_group_label>
    <other_name>Cotara®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed GBM

          -  Clinical Target Volume between 5 and 60 cc (inclusive)

          -  18 to 75 years old (inclusive)

          -  Karnofsky Performance Status ≥ 70 percent

          -  If on steroids dose (± 4mg/day) must be stable for at least two weeks prior to
             screening/baseline visit. If not on steroids for two weeks prior to screening/baseline
             visit are allowed

          -  Adequate hematology

          -  Adequate renal function

          -  Adequate liver function

        Exclusion Criteria:

          -  Infratentorial tumor(s), tumor(s) that communicate with the ventricles or
             intraventricular disease

          -  Bilateral non-contiguous gadolinium enhancing tumor

          -  Diffuse disease (i.e., any satellite lesions less than 1.5 cm from anticipated
             location of any catheter tip or less than two satellite lesions)

          -  Known or suspected allergy to study medication or iodine

          -  Surgical procedure within four weeks of baseline

          -  More than one prior chemotherapy regime or chemotherapy within four weeks
             (nitrosourea-based within six weeks) of baseline

          -  Radiation therapy within four weeks of baseline

          -  Investigational agent within last 30 days

          -  Previous treatment with any chimeric monoclonal antibody

          -  HIV positive

          -  Evidence of active hepatitis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deepak K Gupta, MBBS,MS,MCh</last_name>
    <role>Principal Investigator</role>
    <affiliation>All India Institute of Medical Sciences, New Delhi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barrow Neurological Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania, Department of Neurosurgery</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston,</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amrita Institute of Medical Sciences and Research Center,</name>
      <address>
        <city>Cochin</city>
        <state>Kerala</state>
        <zip>682026</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manipal Institute for Neurological Disorders,</name>
      <address>
        <city>Bangalore</city>
        <zip>560 017</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurosurgery Jaslok Hospital and Research Centre</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>All India Instutite of Medical Sciences</name>
      <address>
        <city>New Delhi</city>
        <zip>110029</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 12, 2008</study_first_submitted>
  <study_first_submitted_qc>May 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2008</study_first_posted>
  <last_update_submitted>April 23, 2014</last_update_submitted>
  <last_update_submitted_qc>April 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>glioblastoma multiforme</keyword>
  <keyword>GBM</keyword>
  <keyword>brain cancer</keyword>
  <keyword>Cotara</keyword>
  <keyword>radioactive isotope</keyword>
  <keyword>monoclonal antibody</keyword>
  <keyword>Glioblastoma multiforme at first relapse</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

